This trial tests the effectiveness of three different novel drugs, including immunotherapy, added to standard treatment for advanced pancreatic cancer.
Researchers want to know if irreversible electroporation (IRE), a minimally invasive surgical technique, makes it easier for chemotherapy to reach pancreatic cancer cells.
A clinical trial combines epigenetic therapy and immunotherapy to make immunotherapy more effective for patients with pancreatic and bile duct cancers.
Researchers are combining TAS-102, an approved drug for colorectal cancer, and nanoliposomal irinotecan, to see if they work on pancreatic and other gastrointestinal cancers.
Researchers are looking at losartan and nivolumab combined with standard protocol of chemotherapy and radiation to see either drug or a combination is more effective.